Meet the Investor Judges at MedCity INVEST
Startups feature prominently at MedCity INVEST from Pitch Perfect to Ask the Investor. Check out the investors who will be judging the startups at INVEST May 22-24 in Chicago and register today!
4 Lessons Health Tech Companies Should Know to Reach $100M ARR
A new study from Bessemer Venture Partners analyzed more than 100 venture-backed healthcare companies to determine the best strategies to scale to $100 million in annual recurring revenue. The report laid out a few main lessons health tech companies should know, such as the importance of nurturing relationships with early customers and making sure efficiency metrics are paid close attention.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
VC Firm SR One Closes $600M Fund to Build ‘Elite Biotechnology Companies’
SR One’s new investment fund is its second one since spinning out of GSK in 2020. The firm says it now has more than $1.5 billion in assets under management.
Biotech Financing Roundup: Mbiomics, Flare Therapeutics, EpiBiologics & More
Flare Therapeutics, EpiBiologics, and Mbiomics are among the biotech companies that recently unveiled new rounds of financing.
Aiming for an Epigenetics Edge, Chroma Raises $135M to Move Closer to the Clinic
GV led Chroma Medicine's Series B financing round, which the biotech will apply toward epigenetic medicines that could offer advantages over other editing technologies. Other recent financings include rounds from Cargo Therapeutics and Transcend Therapeutics.
Why One VC Thinks Women’s Health Is Poised to Take Off Soon
Francesca de Quesada Covey, chief investment officer at investment firm TheVentureCity, believes the women’s health sector will come into its own in the next few years. She said startups focused on improving care delivery will probably have the easiest time raising funds of all the companies in the femtech space.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Which Digital Health Startups Are Most & Least Suited to Raise Capital in 2023?
Last year’s digital health investment trends have left some startups feeling uneasy about their ability to raise capital in the new funding environment. Venture capitalists think companies that have a demonstrable return on investment and serve multiple stakeholders will probably have the easiest time securing capital, while point solutions and startups in crowded markets will face a tougher environment.
Biotech Financing Roundup: Belharra, NextPoint, Pathalys & More
Cancer continues to be a hot area of investment, and it’s the therapeutic focus of several biotech companies that have closed recent rounds of financing. Meanwhile, the investment arm of a big pharmaceutical company has an infusion of new cash to deploy in therapeutic and digital investments.
ROI and Clinical Validation Will Determine Digital Health Startups’ Success in 2023, Investors Say
Going into 2023, investors think the abilities to demonstrate ROI and clinical validation will be the most important factors determining digital health companies' success, according to a new report. While the ROI factor is a given, clinical validation “is the best signal of patient value and historically has been under-captured in digital health," said Sunny Kumar, a partner at GSR Ventures.
How Are Investors Thinking About Healthcare Investment Trends for 2023?
This year has been marked by a rise in health tech layoffs, reduced health tech investment and the continued rise of retail health. What does this mean for healthcare investment in 2023?
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
What’s on the agenda for ENGAGE at HLTH?
Hear from patients, leading provider and payer executives, investors, and healthcare startups about how to improve the patient experience at the event, which kicks off the first day of the HLTH conference. ENGAGE at HLTH is scheduled for November 13 at the Venetian Expo in Las Vegas.
California dreamin’: A VC firm’s vision for West Coast-focused biotech investment
Red Tree Venture Capital has closed a $272 million fund focused on investing in West Coast life sciences companies. The firm’s founders say they’re filling a need by providing financial support for innovations emerging from the region’s academic labs.
Acelyrin’s $300M haul for novel biologic leads a slate of biotech financings
The biggest biotech financing of the past week belongs to a startup developing an immunology drug that could rival blockbuster products sold by big pharmaceutical companies. Cell therapy, cancer, and rare disease also figured into this week’s startup cash hauls.
Redesign Health rakes in $65M to help fund the next generation of health startups
Redesign Health, a company that creates healthcare startups, closed a $65 million Series C funding round. The company has already built more than 40 startups — such as cancer care technology provider Jasper Health, home health company MedArrive and weight loss startup Calibrate.
With new $670M healthcare fund, General Catalyst seeks more health system partners
General Catalyst recently launched a $670 million healthcare investment fund. The fund, called Health Assurance Fund II, seeks to carry on the mission of the venture capital firm’s first healthcare-focused fund, but with a new focus on health system partnerships.